VetStem Biopharma CEO Net Worth

Last Updated Mar 10, 2025
CEO NameRobert J. Harman
NationalityUnited States
Net Worth Estimation$10 million

Robert J. Harman's estimated net worth of around $10 million is primarily attributed to his founding role, equity stake, and executive compensation as CEO of VetStem Biopharma, a leading regenerative veterinary medicine company. The valuation reflects his holdings in the private company, related patents, and income from licensing veterinary stem cell technology.

Robert J. Harman's estimated net worth of $10,000,000 is 14.7% of the maximum and 10 times the minimum CEO net worth within the veterinary business category. This places him well above the minimum but significantly below the top estimated net worth in this field.

Business Category: Veterinary

Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 70000000 USD


Robert J. Harman Performance in VetStem Biopharma

Robert J. Harman, CEO of VetStem Biopharma, demonstrates strategic leadership focused on advancing regenerative medicine through innovative stem cell therapies. His decision-making emphasizes research-driven product development and expanding veterinary regenerative treatment applications, enhancing the company's market position. Under Harman's leadership, VetStem Biopharma has achieved significant growth in clinical adoption and revenue, solidifying its role as a pioneer in animal stem cell therapies.


Latest News

VetStem Biopharma and CEO Dr. Bob Harman: Advancing Veterinary Stem Cell Therapies

VetStem Biopharma, led by founder and CEO Dr. Bob Harman, is a pioneer in veterinary regenerative medicine, having treated over 13,000 animals with stem cell therapies for osteoarthritis and other conditions. The company recently launched FDA-reviewed allogeneic off-the-shelf cell medicine products, and Dr. Harman also serves on the American College of Regenerative Medicine board, bridging veterinary and human regenerative medicine fields.
Source: http://vetstem.com/company.php



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about VetStem Biopharma are subject to change from time to time.

Comments

No comment yet